Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2015

Open Access 01-12-2015 | Original research

The effect of radiation exposure on multidrug resistance: in vitro and in vivo studies using non-small lung cancer cells

Authors: Shohei Kanno, Keita Utsunomiya, Yumiko Kono, Noboru Tanigawa, Satoshi Sawada

Published in: EJNMMI Research | Issue 1/2015

Login to get access

Abstract

Background

Technetium-99m methoxyisobutylisonitrile (Tc MIBI) is a substrate with the same uptake kinetics as doxorubicin. Multidrug resistance (MDR) is a mechanism that impedes chemotherapy of non-small cell lung cancer (NSCLC). We examined the effect of radiation exposure on MDR in NSCLC and the synergy between an MDR modulator, GG918, and radiation, using 99mTc MIBI in vitro and doxorubicin in vivo.

Methods

In vitro NSCLC cells (H1299) were exposed to radiation (3-, 6-, and 9-Gy-irradiated groups) alongside a not-irradiated (0 Gy) group. Technetium-99 metastable methoxyisobutylisonitrile (99mTc MIBI) was administered to cell suspensions at 48 h after irradiation. Cell radioactivity was measured, and C in/C out ratios were calculated and compared. NSCLC cells were also subcutaneously transplanted into the left thigh of nude mice, which were subsequently raised for 2 weeks. Two groups of mice were used: mice exposed to irradiation (9-Gy-irradiated) and those that were not (not-irradiated). Doxorubicin was administered through the caudal vein at 48 h after the irradiation. Using an in vivo imaging system, intratumoural photon counts were measured. To determine the synergy between the MDR modulator and 3- or 6-Gy irradiation, the final GG918 concentration was determined: 0.1 μM (N-H, 3-H, and 6-H groups), 0.001 μM (N-L, 3-L, and 6-L groups), and 0 μM (N-0, 3-0, and 6-0 groups). C in/C out ratios were calculated and compared among the groups.

Results

C in/C out after 6- or 9-Gy irradiation was significantly higher than that of the not-irradiated group (0 Gy). In vivo, fluorescence photon counts were significantly higher in the tumours of 9-Gy-irradiated mice, up to 270 min after administration of doxorubicin, as compared to the not-irradiated mice. The C in/C out ratio in the N-H, 3-H, and 6-H groups was significantly higher than that in the N-0, 3-0, and 6-0 groups. There was no significant difference between C in/C out in the N-L group and that of the N-0 group. However, the C in/C out ratio in the 3-L and 6-L groups was significantly higher than that in the 3-0 and 6-0 groups.

Conclusions

Irradiation decreased MDR in NSCLC cells. In combination with a low-dose MDR modulator, GG918, MDR transport function was synergistically reduced 48 h post-irradiation.
Literature
1.
Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer. 2010;67:257–74.CrossRefPubMed
2.
Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 2006;13:1859–76.CrossRefPubMed
3.
Kibria G, Hatakeyama H, Harashima H. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res. 2014;37:4–15.CrossRefPubMed
4.
Kim YH, Ishii G, Goto K, Ota S, Kubota K, Murata Y, et al. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer. 2009;65:105–11.CrossRefPubMed
5.
Moretti JL, Hauet N, Caglar M, Rebillard O, Burak Z. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur J Nucl Med Mol Imaging. 2005;32:836–42.CrossRefPubMed
6.
Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, et al. Factors in adult acute myeloid leukemia. Clin Cancer Res. 2005;11:7764–72.CrossRefPubMed
7.
Zhou D-C, Simonin G, Faussat A-M, Zittoun R, Marie J-P. Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells. Leukemia. 1997;11:1516–22.CrossRefPubMed
8.
Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, et al. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst. 1991;83:105–10.CrossRefPubMed
9.
Erlichman C, Moore M, Thiessen J, Kerr IG, Walker S, Goodman P, et al. Phase I pharmacokinetic study of combined with doxorubicin. Cancer Res. 1993;53:4837–42.PubMed
10.
Utsunomiya K, Ballinger JR, Piquette-Miller M, Rauth AM, Tang W, Su ZF, et al. Comparison of the accumulation and efflux kinetics of technetium-99 m sestamibi and technetium-99 m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med. 2000;27:1786–92.CrossRefPubMed
11.
Ballinger JR, Hua HA, Berry BW, Firby P, Boxen I. Technetium-99 m-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun. 1995;16:253–7.CrossRefPubMed
12.
Tatsumi M, Tsuruo T, Nishimura T. Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99 m-MIBI imaging. Eur J Nucl Med. 2002;29:288–4.CrossRef
13.
Takahashi A, Yano T, Matsumoto H, Ohnishi K, Ishioka N, Ohnishi T. Apoptosis induced by high-LET radiation is not affected by cellular p53 gene status. Int J Radiat Biol. 2005;81:581–6.CrossRefPubMed
14.
Iwasaki T, Mukai M, Tsujimura T, Tatsuta M, Nakamura H, Terada N, et al. Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model. Int J Cancer. 2002;100:381–7.CrossRefPubMed
15.
Vanhoefer U, Cao S, Minderman H, Tóth K, Scheper RJ, Slovak ML, et al. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res. 1996;2:369–77.PubMed
16.
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–68.PubMed
17.
Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridone carboxamide derivative. Cancer Res. 1993;53:4595–602.PubMed
18.
Shareef MM, Brown B, Shajahan S, Sathishkumar S, Arnold SM, Mohiuddin M, et al. Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-KB and NF-Y activation in oral carcinoma cells. Mol Cancer Res. 2008;6:89–98.CrossRefPubMed
19.
Gupta S, Koru-Sengul T, Arnold SM, Devi GR, Mohiuddin M, Ahmed MM. Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells. Mol Cancer Ther. 2011;10:292–302.CrossRefPubMed
20.
Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204:216–37.CrossRefPubMed
21.
Del Vecchio S, Salvatore M. 99mTc-MIBI in the evaluation of breast cancer biology. Eur J Nucl Med Mol Imaging. 2004;31:S88–96.CrossRefPubMed
22.
Mohan HK, Miles KA. Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med. 2009;50:377–81.CrossRef
23.
Kao CH, Hsieh JF, Tsai SC, Ho YJ, Lee JK. Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99 m methoxyisobutylisonitrile chest single-photon-emission computed tomography. Clin Cancer Res. 2000;6:820–4.PubMed
24.
Dirlik A, Burak Z, Goksel T, Erinc R, Karakus H, Ozcan Z, et al. The role of Tc-99 m sestamibi imaging in predicting clinical response to chemotherapy in lung cancer. Ann Nucl Med. 2002;16:103–8.CrossRefPubMed
25.
Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JE, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol. 1987;5:641–7.PubMed
26.
Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001;61:749–58.PubMed
Metadata
Title
The effect of radiation exposure on multidrug resistance: in vitro and in vivo studies using non-small lung cancer cells
Authors
Shohei Kanno
Keita Utsunomiya
Yumiko Kono
Noboru Tanigawa
Satoshi Sawada
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2015
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-015-0091-5

Other articles of this Issue 1/2015

EJNMMI Research 1/2015 Go to the issue

Original research

Gene expression signature in mouse thyroid tissue after 131I and 211At exposure

Original research

Comparison of 4′-[methyl-11C]thiothymidine (11C-4DST) and 3′-deoxy-3′-[18F]fluorothymidine (18F-FLT) PET/CT in human brain glioma imaging

Original research

Longitudinal tumor hypoxia imaging with [18F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity

Original research

Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5 % glucose during administration

Original research

Evaluation of the specificity of [18F]fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [18F]FDG and impact of rituximab therapy

Original research

Non-invasive imaging of implanted peritoneal carcinomatosis in mice using PET and bioluminescence imaging